Learn how AI is transforming predictions of drug-induced liver injury and aiding drug development for safer therapeutics.

Machine learning models are designed to analyze large, heterogeneous datasets and identify complex relationships without ...

AI can improve cancer outcome predictions by generating synthetic molecular data from routine pathology images, according to new research ...

Illumina launched the Billion Cell Atlas to train AI on one billion single cells. AstraZeneca, Merck and Lilly are founding ...

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

N2OFF, Inc. (NASDAQ: NITO) ('N2OFF” and the 'Company”), a drug discovery company that is also investing in solar energy ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is ...

AI Impact explores why AI security has outgrown human oversight, plus pricing gains, health care insight and key AI moves in ...

Organoids have now evolved beyond simple experimental models to become next-generation biological platforms that precisely replicate human organ ...

Cancer immunity and immunotherapy research increasingly recognizes that chronic inflammation is a major driver of tumorigenesis, yet the complex and dynamic ...